OpenCharities

The Smith-Magenis Syndrome (sms) Foundation UK CIO

The Smith-Magenis Syndrome (s.m.s.) Foundation UK

Country
England & Wales
Charity number
1186647
Status
Registered
Registered
Nov. 28, 2019
Legal form
CIO

Address

Address
61 High Street
PEWSEY
Wiltshire
SN9 5AF

Activities

We are a small charity that supports families living with Smith-Magenis syndrome (SMS), a rare condition that occurs once in every 15-25,000 births. People with SMS have complex needs and behaviours, along with a learning disability. Our aim is to provide all caregivers and professionals with the knowledge and understanding to feel empowered and confident to support a person with SMS.

Objects: The Objects Of The CIO Are:a) To Preserve And Protect The Health And Promote The Relief Of Persons Affected By Smith-Magenis Syndrome And Any Associated Condition,b) To Advance The Education Of The Medical Profession And The General Public On The Subject Of Smith-Magenis Syndrome And Its Implications For The Family,c) To Advance Public Education By Promoting Research Into The Management Of Smith-Magenis Syndrome And To Publish Useful Results Thereof And To Support Organisations Promoting Research Into Smith-Magenis Syndrome.

Classification

How
Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
What
General Charitable Purposes, The Advancement Of Health Or Saving Of Lives, Disability
Who
People With Disabilities

Areas of operation

Country
Northern Ireland, Scotland
Region
Throughout England And Wales

Finances

Period end Income Expenditure
June 30, 2024 £81,579 £84,648
June 30, 2023 £82,983 £89,727
June 30, 2022 £105,691 £135,109
June 30, 2021 £78,468 £98,206
June 30, 2020 £13,388 £7,696

Trustees

Name Appointed
Hazel Wotherspoon (Chair) Nov. 17, 2019
Alistair Hudson Feb. 5, 2025
Alvar de Wolff Feb. 5, 2025
Andrew Bird Feb. 5, 2025
Emma Riddell Nov. 17, 2019
Jacqueline Jenkins July 1, 2023
Jayne Marie Dainty Jan. 25, 2022
Laurie Grainger Feb. 5, 2025
Michael Pearson Nov. 16, 2019
William Stevenson Feb. 1, 2025